Literature DB >> 28350897

Transforming Concepts Into Clinical Trials and Creating a Multisite Network: The Leadership and Operations Center of the Antibacterial Resistance Leadership Group.

Heather R Cross1, Anthony Harris2, Rebekka M Arias1, Henry F Chip Chambers3, Vance G Fowler1,4.   

Abstract

The Leadership and Operations Center (LOC) is responsible for facilitating, coordinating, and implementing the Antibacterial Resistance Leadership Group (ARLG) scientific agenda by engaging thought leaders; soliciting research proposals; and developing the processes, tools, and infrastructure required to operationalize studies and create and sustain the ARLG network. These efforts are ongoing as new projects are developed and the network expands and grows to address the ever-changing priorities in antibacterial resistance. This article describes the innovations, accomplishments, and opportunities of the LOC since the inception of the ARLG in 2013.
© The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  antibacterial resistance; clinical trial network; infectious disease; mentoring.

Mesh:

Year:  2017        PMID: 28350897      PMCID: PMC5850016          DOI: 10.1093/cid/ciw825

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  14 in total

1.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

Review 2.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America.

Authors:  Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

3.  Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing.

Authors:  Ritu Banerjee; Christine B Teng; Scott A Cunningham; Sherry M Ihde; James M Steckelberg; James P Moriarty; Nilay D Shah; Jayawant N Mandrekar; Robin Patel
Journal:  Clin Infect Dis       Date:  2015-07-20       Impact factor: 9.079

4.  Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group.

Authors:  Claudia Manca; Carol Hill; Andrea M Hujer; Robin Patel; Scott R Evans; Robert A Bonomo; Barry N Kreiswirth
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 5.  The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group.

Authors:  Deverick J Anderson; Timothy C Jenkins; Scott R Evans; Anthony D Harris; Robert A Weinstein; Pranita D Tamma; Jennifer H Han; Ritu Banerjee; Robin Patel; Theoklis Zaoutis; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 6.  Innovative clinical trial design for pediatric therapeutics.

Authors:  Matthew M Laughon; Daniel K Benjamin; Edmund V Capparelli; Gregory L Kearns; Katherine Berezny; Ian M Paul; Kelly Wade; Jeff Barrett; Phillip Brian Smith; Michael Cohen-Wolkowiez
Journal:  Expert Rev Clin Pharmacol       Date:  2011-09       Impact factor: 5.045

7.  Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

Authors:  Pranita D Tamma; Jennifer H Han; Clare Rock; Anthony D Harris; Ebbing Lautenbach; Alice J Hsu; Edina Avdic; Sara E Cosgrove
Journal:  Clin Infect Dis       Date:  2015-01-13       Impact factor: 9.079

8.  Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network.

Authors:  David van Duin; Federico Perez; Susan D Rudin; Eric Cober; Jennifer Hanrahan; Julie Ziegler; Raymond Webber; Jacqueline Fox; Pamela Mason; Sandra S Richter; Marianne Cline; Geraldine S Hall; Keith S Kaye; Michael R Jacobs; Robert C Kalayjian; Robert A Salata; Julia A Segre; Sean Conlan; Scott Evans; Vance G Fowler; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

9.  Dissemination of high-risk clones of extensively drug-resistant Pseudomonas aeruginosa in colombia.

Authors:  Adriana Correa; Rosa Del Campo; Marcela Perenguez; Victor M Blanco; Mercedes Rodríguez-Baños; Federico Perez; Juan J Maya; Laura Rojas; Rafael Cantón; Cesar A Arias; Maria V Villegas
Journal:  Antimicrob Agents Chemother       Date:  2015-01-20       Impact factor: 5.191

10.  Public reporting of health care-associated surveillance data: recommendations from the healthcare infection control practices advisory committee.

Authors:  Thomas R Talbot; Dale W Bratzler; Ruth M Carrico; Daniel J Diekema; Mary K Hayden; Susan S Huang; Deborah S Yokoe; Neil O Fishman
Journal:  Ann Intern Med       Date:  2013-11-05       Impact factor: 25.391

View more
  4 in total

Review 1.  Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group.

Authors:  Ephraim L Tsalik; Elizabeth Petzold; Barry N Kreiswirth; Robert A Bonomo; Ritu Banerjee; Ebbing Lautenbach; Scott R Evans; Kimberly E Hanson; Jeffrey D Klausner; Robin Patel
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

2.  The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Authors:  Henry F Chip Chambers; Heather R Cross; Scott R Evans; Barry N Kreiswirth; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 3.  Gram-Positive Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Sarah B Doernberg; Thomas P Lodise; Joshua T Thaden; Jose M Munita; Sara E Cosgrove; Cesar A Arias; Helen W Boucher; G Ralph Corey; Franklin D Lowy; Barbara Murray; Loren G Miller; Thomas L Holland
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

Review 4.  Gram-Negative Bacterial Infections: Research Priorities, Accomplishments, and Future Directions of the Antibacterial Resistance Leadership Group.

Authors:  Yohei Doi; Robert A Bonomo; David C Hooper; Keith S Kaye; James R Johnson; Cornelius J Clancy; Joshua T Thaden; Martin E Stryjewski; David van Duin
Journal:  Clin Infect Dis       Date:  2017-03-15       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.